HKU Scholars Hub: Browsing DSpace

Browsing by Author Wedemeyer, H

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 4 to 13 of 13 < previous

	Title	Author(s)	Issue Date	Views
	HBsAg loss after nucleo(s)tide analogue withdrawal: relationship with viral antigen levels and hbv genotype Proceeding/Conference:Poster presentation at the AASLD The Liver Meeting, November 12-15. 2021. Hepatology	Sonneveld, MJ Chiu, S-M Park, JY Kaewdech, A Seto, WKW Tanaka, Y Carey, I Papatheodoridi, M Van Bömmel, F Brakenhoff, S Berg, T Zoulim, F Ahn, SH Dalekos, GN Erler, NS Zu Siederdissen, CN Wedemeyer, H Cornberg, M Yuen, RMF Agarwal, K Boonstra, A Buti, M Piratvisuth, T Papatheodoridis, G Chen, CH Maasoumy, B CREATE study group,	2021
	HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT CLINICAL RELAPSE AND HBSAG LOSS IN HBEAG NEGATIVE PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY Journal:Gastroenterology	Sonneveld, MJ Chiu, S-M Park, JY Brakenhoff, SM Kaewdech, A Seto, WK Tanaka, Y Carey, I Papatheodoridi, M Colombatto, P Van Bömmel, F Janssen, HL Berg, T Zoulim, F Ahn, SH Dalekos, GN Erler, NS Brunetto, M Wedemeyer, H Cornberg, M Yuen, MF Agarwal, K Boonstra, A Buti, M Piratvisuth, T Papatheodoridis, G Chen, C-H Maasoumy, B	26-Sep-2023
	Hepatitis B surface antigen (HBsAg) reductions following administration of a single dose of VIR-3434, an investigational, neutralizing, vaccinal monoclonal antibody: first experience in participants with high HBsAg burden Proceeding/Conference:Hepatology International	Yuen, MF Agarwal, K Wedemeyer, H Cloutier, D Shen, L Arizpe, A Hassani, A Gupta, SV Hwang, C Gane, E Agarwal, K	31-Mar-2023
	Lower Pre-Treatment HBV DNA Levels Are Associated With Better Off-Treatment Outcomes After Nucleo(S)Tide Analogue Withdrawal In Patients With Chronic Hepatitis B Proceeding/Conference:Hepatology	Sonneveld, MJ Chiu, SM Park, JY Brakenhoff, S Kaewdech, A Seto, WK Tanaka, Y Carey, I Papatheodoridi, M Colombatto, P Van Bommel, F Berg, T Zoulim, F Ahn, SH Dalekos, GN Erler, NS Brunetto, M Wedemeyer, H Cornberg, M Yuen, MF Agarwal, K Boonstra, A Buti, M Piratvisuth, T Papatheodoridis, GV Chen, CH Maasoumy, B	31-Oct-2022
	Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels – a multicenter study (CREATE) Proceeding/Conference:Hepatology	Sonneveld, MJ Park, JY Kaewdech, A Seto, WKW Tanaka, Y Carey, I Papatheodoridi, M Van Bömmel, F Berg, T Zoulim, F Ahn, SH Dalekos, GN Erier, NS Höner zu SiederdissenC, C Wedemeyer, H Comberg, M Yuen, RMF Agarwal, K Boonstra, A Ferret, MAB Piratvisuth, T Papatheodoridis, G Maasoumy, B CREATE study group,	2020	12
	Prediction Of Sustained Response After Nucleo(s)tide Analogue Cessation Using Hbsag And Hbcrag Levels – A Multicenter Study (create) Journal:Clinical Gastroenterology and Hepatology	Sonneveld, MJ Park, JY Kaewdech, A Seto, WK Tanaka, Y Carey, I Papatheodoridi, M van Bommel, F Berg, T Zoulim, F Ahn, SH Dalekos, GN Erler, NS Honer zu Siederdissen, C Wedemeyer, H Cornberg, M Yuen, MF Agarwal, K Boonstra, A Buti, M Piratvisuth, T Papatheodoridis, G Maasoumy, B	2020	36
	Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels Journal:Journal of Hepatology	Sonneveld, MJ Chiu, SM Park, JY Brakenhoff, SM Kaewdech, A Seto, WKW Tanaka, Y Carey, I Papatheodoridi, M van Bommel, F Berg, T Zoulim, F Ahn, SH Dalekos, GS Erler, NS Honer zu Siederdissen, C Wedemeyer, H Cornberg, M Yuen, RMF Agarwal, K Boonstra, A Buti, M Piratvisuth, T Papatheodoridis, G Chen, CH Maasoumy, B	2022	6
	Rapid HBsAg reduction in chronic hepatitis B virus infection: preliminary results from a phase 1 study evaluating a single dose of VIR-3434, a novel neutralizing, vaccinal monoclonal antibody Proceeding/Conference:Poster presentation at the AASLD The Liver Meeting, November 12-15. 2021. Hepatology	Agarwal, K Yuen, RMF Wedemeyer, H Arizpe, A Shen, L Cloutier, D Tay, C Gupta, SV Fanget, MC Dholakiya, SL Seu, L Cathcart, AL Hwang, C Pang, PS Gane, EJ	2021
	Reduction in Hepatitis B Viral DNA and Hepatitis B Surface Antigen Following Administration of a Single Dose of VIR-3434, an Investigational Neutralizing Monoclonal Antibody: First Experience in a Population With Viremia Proceeding/Conference:The Liver Meeting 2022: American Association for the Study of Liver Diseases (AASLD) (04/11/2022-08/11/2022, Washington, USA)	Agarwal, K Yuen, MF Wedemeyer, H Cloutier, D Shen, L Arizpe, A Gupta, SV Fanget, M Seu, L Cathcart, AL Lau, AH Hwang, C Gane, E	31-Oct-2022
	The case for simplifying and using absolute targets for viral hepatitis elimination goals Journal:Journal of Viral Hepatitis	Razavi, H Blach, S Razavi-Shearer, D Abaalkhail, F Abbas, Z Abdallah, A Abrao Ferreira, P Abu Raddad, LJ Adda, D Agarwai, K Aghemo, A Ahmed, A Al‐Busafi, SA Al‐hamoudi, W Al‐Kaabi, S Al‐Romaihi, H Aljarallah, B AlNaamani, K Alqahtani, S Alswat, K Altraif, I Thein, H-H Thompson, P Tolmane, L Toy, M Valantinas, J Van de Vijver, D Vélez‐Möller, P Vince, A Waked, I Wang, S Wedemeyer, H Wong, V Xie, Q Yamada, S Yang, H-I Yesmembetov, K Yilmaz, Y Younossi, Z Yu, M-L Yuen, RMF Yurdaydin, C Yusuf, A Zekry, A Zeuzem, S	2021	3

Showing results 4 to 13 of 13 < previous